SciFi Futures
← Capabilities
Biotech & Medicine/Component technology

Precise in vivo gene editing

Delivering CRISPR, base or prime editors to the right cells in a living body to change DNA precisely without harmful off-target effects.

State of the art

Casgevy approved 2023 (ex vivo); first personalized in vivo base-editing therapy given to an infant in 2025.

What’s blocking it
  • Delivery to tissues beyond liver
  • Long-term off-target safety

Who’s working on it

  • Its Phase 3 HAELO trial of lonvo-z (NTLA-2002) in hereditary angioedema met the primary and all key secondary endpoints in April 2026, the first Phase 3 data for any in vivo gene-editing therapy

  • David LiuResearcher
    Broad Institute of MIT and Harvard

    Invented base and prime editing; his lab designed the base editor used for baby KJ in 2025 and is extending prime editing to disease-agnostic suppressor-tRNA approaches

  • Kiran MusunuruResearcher
    University of Pennsylvania and Children's Hospital of Philadelphia

    Led the first patient-specific in vivo base-editing therapy, an LNP-delivered editor given to an infant with CPS1 deficiency (NEJM, May 2025), and is building umbrella platforms for urea-cycle disorders and PKU

  • NIH Common Fund program funding targeted delivery technologies, safety assays and platform clinical-trial pathways; it underwrote the preclinical work behind the KJ therapy

  • Running BEAM-302 for alpha-1 antitrypsin deficiency and in 2026 made in vivo LNP delivery its priority even for sickle cell disease, the clearest industry bet that in vivo beats ex vivo

  • Capstan TherapeuticsStartup

    Built targeted LNPs that reprogram T cells in vivo rather than in a facility; acquired by AbbVie in 2025 for about $2.1B, pricing extrahepatic delivery

What to invest in

KindInvestmentScale
researchTissue-targeted delivery vehicles (LNPs, engineered capsids)$$$ $100M – $1B

Sci-fi concepts in reach

Engineered human adaptation to other worldsdirectWhole-body rejuvenation treatmentdirectIntelligence amplification treatmentdirectNexus-6 androids (replicants)indirect